# Iza-Bren Shows an Early Signal in SCLC

> The EGFR-HER3 antibody-drug conjugate produced responses in a 52-patient phase Ib small-cell lung cancer cohort, but the uncontrolled study cannot establish superiority or a new standard of care.

_Source: Peer-reviewed JCO phase Ib report, verified against PubMed, Crossref and ClinicalTrials.gov registrations NCT05194982 and NCT06500026 · 2026-08-23 · 7 min read · Verified against primary sources_

Canonical: https://iyu.app/e/iza-bren-phase1b-relapsed-small-cell-lung-cancer

## The 60-second version

Iza-bren produced a 48.1 percent response rate in a 52-patient phase Ib cohort with relapsed extensive-stage small-cell lung cancer.

**Key points**

- The uncontrolled trial measured median progression-free survival of 4.1 months and overall survival of 12.2 months.
- A 22-patient second-line subgroup had a 72.7 percent response rate, with wide uncertainty and no randomization.
- Common treatment-related events included neutropenia, thrombocytopenia, anaemia and leukopenia.
- HER3 was only an exploratory biomarker, not a validated treatment-selection test.
- A 722-patient randomized phase III trial against topotecan is active but has no posted result.

**Verdict.** A credible early efficacy signal, but randomized survival and comparative safety must decide whether iza-bren changes practice.

## Full explainer

> **⚑ Caveat:** Evidence boundary: this was a **52-patient, open-label, uncontrolled phase Ib cohort**. Response and survival estimates are real measurements, but they do not establish superiority or a new standard of care.


### Bottom line — A promising signal that needs a comparator

Iza-bren is an EGFR-HER3 bispecific antibody-drug conjugate. In previously treated extensive-stage small-cell lung cancer, the overall objective response rate was **48.1%**.

The second-line subgroup produced the highest response estimate, but it contained only 22 patients and was not randomized. A phase III comparison against topotecan is underway and has not reported results.

- **52** — patients in the SCLC expansion
- **48.1%** — overall objective response rate
- **4.1 mo** — median progression-free survival
- **12.2 mo** — median overall survival


### Treatment — What iza-bren is and how it was given

The antibody binds EGFR and HER3 and delivers a cytotoxic payload. Patients received **2.5 mg/kg on days 1 and 8 of each three-week cycle**, not a single dose once every three weeks.

- **Trial phase:** Open-label phase Ib dose expansion within NCT05194982.
- **Population:** Extensive-stage SCLC after progression on prior systemic therapy.
- **Primary focus:** Objective response plus safety and tolerability.
- **Control arm:** None; every patient in the reported cohort received iza-bren.


### Subgroup — Why 72.7 percent needs caution

Among 22 patients treated in the second-line setting, the response rate was **72.7%**, with a 95% confidence interval of 49.8% to 89.3%. Median progression-free survival was 6.2 months and overall survival 15.0 months.

> A striking subgroup estimate is a reason to run a randomized trial, not a substitute for one.

The subgroup was small and selected after treatment history was known. Without random allocation, differences in prognosis, prior therapy and follow-up can influence the result.


### Safety — Blood toxicities were common

The most common treatment-related adverse events were neutropenia, thrombocytopenia, anaemia and leukopenia. These are clinically important because they can increase infection, fatigue and bleeding risks.

- **No randomized benefit estimate:** there was no standard-treatment arm.
- **Small subgroup:** the strongest response estimate came from 22 patients.
- **Biomarker exploratory:** HER3 positivity is not yet a validated selection test.
- **Mature safety needed:** comparative rates of severe toxicity and discontinuation matter.
- **Industry involvement:** the trial sponsor and collaborators are represented among the authors.

> **i** ClinicalTrials.gov lists Sichuan Baili Pharmaceutical as sponsor and SystImmune as collaborator for the phase I study. Several authors are affiliated with Baili-Bio, SystImmune or Biokin.


### Phase III — The decisive test is already underway

NCT06500026 randomized 722 patients to iza-bren or topotecan after prior platinum and PD-1 or PD-L1 therapy. Overall survival is the primary endpoint. The registry lists the trial as active, not recruiting, with no result posted.

Patients should not change care from this report alone. The useful action is to discuss established options and legitimate trial eligibility with an oncology team while waiting for randomized survival and safety data.


## Primary sources

- [Telegram post 1430](https://t.me/CNSmydream/1430)
- [Journal of Clinical Oncology paper](https://doi.org/10.1200/JCO-26-00243)
- [PubMed record](https://pubmed.ncbi.nlm.nih.gov/42497381/)
- [Phase I registration NCT05194982](https://clinicaltrials.gov/study/NCT05194982)
- [Phase III registration NCT06500026](https://clinicaltrials.gov/study/NCT06500026)
- [Crossref metadata and abstract](https://api.crossref.org/works/10.1200/JCO-26-00243)

---
_Published by iyu (https://iyu.app) — the day's AI news, checked against primary sources and rewritten in plain language. Free to quote with attribution and a link to the canonical URL._